CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2015; 36(04): 201-206
DOI: 10.4103/0971-5851.171534
EDITORIAL

HPV vaccine: One, two, or three doses for cervical cancer prevention?

Gauravi A. Mishra
Department of Preventive Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Sharmila A. Pimple
Department of Preventive Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Surendra S. Shastri
Department of Preventive Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
› Author Affiliations
Financial support and sponsorship Nil.


Publication History

Publication Date:
12 July 2021 (online)

© 2015. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012, v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://www.globocan.iarc.fr. [Last accessed on 2015 Oct 27].
  • 2 Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89,43:465-91.
  • 3 Dochez C, Bogers JJ, Verhelst R, Rees H. HPV vaccines to prevent cervical cancer and genital warts: An update. Vaccine 2014;32:1595-601.
  • 4 Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011;103:1444-51.
  • 5 Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30 Suppl 5:F123-38.
  • 6 Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-63.
  • 7 Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995;92:11553-7.
  • 8 Ahuja A, Anderson SM, Khalil A, Shlomchik MJ. Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci U S A 2008;105:4802-7.
  • 9 Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
  • 10 FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
  • 11 Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70.
  • 12 Herrero R, Hildesheim A, Rodríguez AC, Wacholder S, Bratti C, Solomon D, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008;26:4795-808.
  • 13 Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14.
  • 14 Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009;5:705-19.
  • 15 Einstein M. On behalf of the HPV-010 study group. Comparison of immunogenicity of two prophylactic human papillomavirus (HPV) vaccines as month 48. Int J Gynecol Obstet 2012;119S3:S334.
  • 16 D′Addario M, Scott P, Redmond S, Low N. HPV Vaccines: Systematic Review of Literature on Alternative Vaccination Schedules. Report to WHO. Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland (24 th June, 2014). In: Evidence Based Recommendations on Human Papilloma Virus (HPV) Schedules: Background Paper for SAGE Discussions. Annex 1. Geneva: World Health Organization; 2014. Available from: http://www.who.int/immunization/sage/meetings/2014/april/1_HPV_Evidence_based_recommendationsWHO_with_Appendices2_3.pdf?ua=1. [Last accessed on 2015 Nov 06].
  • 17 Printz C. One HPV vaccine dose may prevent cervical cancer. Cancer 2014;120:772-3.
  • 18 Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: Combined analysis of data from the costa rica vaccine and PATRICIA trials. Lancet Oncol 2015;16:775-86.
  • 19 Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicenter prospective cohort study. The Lancet Oncology 2015. (In Press).
  • 20 Brotherton JML, Malloy M, Budd AC, Saville M, Drennan KT, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia. Papillomavirus Research. Available online 15 June 2015 (In Press).
  • 21 Olley M. Changes to the Human Papillomavirus (HPV) Vaccine Schedule 2014/15 Advice for Healthcare Professionals. Published March, 2015 v2. PHE Publications Gateway Number: 2014814.
  • 22 Jit M, Brisson M, Laprise JF, Choi YH. Comparison of two dose and three dose human papillomavirus vaccine schedules: Cost effectiveness analysis based on transmission model. BMJ 2015;350:g7584.
  • 23 Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: Results from a randomized study. Hum Vaccin 2011;7:1374-86.
  • 24 Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013;6:1242-50.
  • 25 Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-35.
  • 26 Brotherton JM. Could one dose of bivalent HPV vaccine prevent cervical cancer? Lancet Oncol 2015;16:739-40.
  • 27 Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372:711-23.
  • 28 Roden RB, Yutzy WH 4 th , Fallon R, Inglis S, Lowy DR, Schiller JT. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 2000;270:254-7.
  • 29 Gambhira R, Gravitt PE, Bossis I, Stern PL, Viscidi RP, Roden RB. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res 2006;66:11120-4.
  • 30 Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, et al. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 2007;81:13927-31.
  • 31 Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, et al. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 2007;81:11585-92.
  • 32 Schiller JT, Müller M. Next generation prophylactic human papillomavirus vaccines. Lancet Oncol 2015;16:e217-25.
  • 33 Bharati K, Ganguly NK. Does India need an indigenous HPV vaccine and why? J Public Health Policy 2013;34:272-87.